Renalytix, the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic for kidney disease, has selected EVERSANA, a global leader in life-science commercialization services, to expand the company’s commercial footprint for KidneyIntelX, a prognostic device for patients with diabetic kidney disease. EVERSANA will launch its field deployment and training solutions with Renalytix to primary care providers across key parts of the United States later this summer. These EVERSANA-supported deployments complement Renalytix existing sales efforts in major markets including New York and Illinois where comprehensive insurance coverage is now available for individuals living with diabetes and kidney disease.
EVERSANA announced that it has established a strategic alliance with the China Resources Pharmaceutical Commercial Group, a leading pharmaceutical distribution enterprise based in Beijing. Together, the two organizations will collaborate on helping expand access to innovative healthcare solutions that are available both in and outside of China to ultimately help more patients globally discover new treatment options for a variety of disease states.
Boutique consultancy Skysis merged with its larger sibling Avalere Health, spawning a single U.S. market access unit within parent Fishawack Health. As part of the merger, Skysis will be retired as a brand and its staff will be integrated within Avalere’s policy, access, value and evidence team.
IntegriChain and Verato, the identity experts for healthcare, announced a technology partnership. IntegriChain will utilize Verato’s healthcare master data management (hMDM) solution to create a new ICyte® Secure PHI Vault for securing protected health information (PHI) and personal identifiable information (PII). The vault receives and stores identifiable patient information – ingested from a variety of sources including specialty pharmacies, hubs, and claims data – and utilizes best-in-class data science and patient matching technology from Verato to securely and accurately match patients across disparate data sets. The vault also seamlessly integrates tokenized PHI and PII into ICyte Patient Data Solutions for accurate insights on the patient journey.
IntegriChain and Knipper Health, a healthcare solutions company, are teaming up in a non-exclusive venture to support emerging manufacturers. Through the agreement, the organizations are expected to provide assistance with products that need comprehensive third-party logistics (3PL) services, order-to-cash, government pricing, and claims adjudication support.
IntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution.
McKesson Ventures has participated in a $17.5 million Series A round for RxLightning, a platform for streamlining access and affordability for specialty medications. This brings the total the company has raised since its inception to $20.5 million. With RxLightning, healthcare providers—from those practicing at independent clinics to large health systems—leverage a streamlined workflow to complete the multi-step specialty medication onboarding process in a matter of minutes. RxLightning is becoming the single destination to enroll patients for any specialty medication, brand or generic, at any specialty pharmacy. The company has digitized forms for more than 1,200 specialty drugs with custom logic and smart-pick menus, and continuously adds new forms for new medications as they enter the market. The platform also automates the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program, confirms patient eligibility and coverage, and streamlines enrollment in financial assistance programs.
Takeaway: AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 70 companies